版本:
中国

BRIEF-Vical and Astellas study on CMV vaccine fails to meet its primary endpoint

Sept 19 Vical Inc

* Results from study demonstrated that trial did not meet its primary endpoint

* Secondary endpoints of CMV-associated disease,CMV-specific antiviral therapy blinded adjudication committee,were similar in both treatment groups

* Vical and Astellas announce topline results from a phase 2 study of investigational cytomegalovirus (CMV) vaccine (asp0113) in kidney transplant patients

* "we continue to focus on execution of our phase 3 study in hematopoietic cell transplant (HCT) recipients" Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐